ThursdayOct 24, 2024 12:45 pm

CBDNewsBreaks – CBD Life Sciences Inc. (CBDL) Poised to Become Game Changer in the Hemp Industry

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70 billion industry and, with its innovative product line and strategic market positioning, standing ready to deliver unparalleled returns for shareholders. “The U.S. is on the verge of a historic shift. With the Biden administration, led by Vice President Kamala Harris, taking bold steps toward federal marijuana legalization, the opportunities for companies in the cannabis and CBD sectors are poised to skyrocket,” the announcement reads. “According to industry projections, the legal cannabis market in the U.S. is expected to surpass $70 billion by 2028, driven by…

Continue Reading

WednesdayOct 16, 2024 12:20 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Subsidiary Negotiating Pharma Cannabis Supply Deal with Australian Firm

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, today announced that its Colombian subsidiary is in negotiations with an Australian pharmaceutical company to supply medical-grade cannabis. The agreement is expected to generate between $100,000 and $200,000 in monthly revenue once operations begin. MedCana's CEO, Jose Gabriel Diaz, emphasized the significance of this deal in the company’s ongoing global expansion aimed at meeting the rising demand for high-quality cannabis products. To view the full press release, visit https://cnw.fm/uIXJh About Software Effective Solutions Software Effective Solutions/MedCana is a holding company…

Continue Reading

WednesdayOct 09, 2024 12:35 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, is reporting on recent acquisitions and cannabis licenses associated with the acquisitions. According to the announcement, the new acquisitions and licenses, which will add $1.6 million to company assets for the third quarter, are designed to bolster the company's cannabis portfolio globally and solidify its position as a leading force in the cannabis sector. According to the announcement, the licenses include seven produce, process and sell CBD licenses; seven produce, process and sell THC licenses; seven fabrication of products containing…

Continue Reading

FridaySep 27, 2024 3:20 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Continue Reading

ThursdaySep 12, 2024 12:05 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all…

Continue Reading

ThursdaySep 05, 2024 11:16 am

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

Continue Reading

TuesdaySep 03, 2024 12:24 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

Continue Reading

ThursdayAug 29, 2024 12:12 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the tolerability and additional pharmacokinetic (“PK”) results from its human pilot study #2, GLP-1-H24-2, have been received. According to the results, absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus tablets, even under “fed” conditions. The results also show that DehydraTECH-treated Rybelsus does absorb through a mouth-melt product format. “We were pleased to find that none of the nine people taking the DehydraTECH-processed Rybelsus swallowed as a capsule experienced any adverse events whatsoever,” the company stated in the press release. “However, of the nine human…

Continue Reading

ThursdayAug 22, 2024 10:22 am

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Subsidiary Secures Motor Carrier Authority, DOT Licenses

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced that its wholly owned subsidiary, LE Logistics, LLC (LE”), has officially secured the Motor Carrier Authority (“MC”) and U.S. Department of Transport (“DOT”) licenses. This development positions LE to immediately launch its freight division under the Golden Triangle Ventures umbrella and sets the stage for a stronger and more compliant operational foundation. In addition, it positions LE to start operations with its initial fleet of assets under a brand-new, clean operating license. The licenses also prime LE to execute its strategy of operating a larger fleet of assets, driving…

Continue Reading

WednesdayAug 21, 2024 12:39 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria’s belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control. Additionally, select DehydraTECH-CBD…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722